The initial phase of the competition aims to attract eligible participants to submit innovative proposals on target neuromodulation therapies.
The National Institute of Health (NIH) recently launched phase 1 of the Neuromod Prize – part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program from the NIH Common Fund. The $9.8 million initiative aims to accelerate the development of targeted neuromodulation therapies focusing on the peripheral nervous systems to treat diseases in human.
The first phase calls on scientists, engineers, and clinicians to submit novel concepts and plans for development, as well as their expectations for clinical impact. Up to 8 winners will be selected in phase 1, each with potential to receive up to $800,000 from the prize pool. Phase 1 winners will also be exclusively invited to participate in phase 2 of the competition, which aims to transfer those novel concepts to preclinical studies. Phase 3, expected to roll out in Summer 2023, will focus on moving their preclinical work into advanced translational and clinical studies as a critical step towards the regulatory approvals needed to bring new neuromodulation therapies to market.
Read more in the NIH Press Release here.
Potential applicants can learn about the Neuromod Prize during the virtual information and Q&A session on Monday, February 7 from 1:00 to 2:00 pm EST. Register for the event here.
Learn more about the Neuromod Prize at neuromodprize.com.